Capricor Therapeutics, Inc. (CAPR)
NASDAQ:CAPR
Want to see CAPR full AI Analyst Report?
CAPR Stock Chart & Stats
$34.70
-$0.36(-2.53%)
At close: 4:00 PM EST
$34.70
-$0.36(-2.53%)
Day’s Range― - ―
52-Week Range$4.30 - $40.37
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.09M
Market Cap
$1.67B
Enterprise Value$1.24B
Total Cash (Recent Filing)$278.61M
Total Debt (Recent Filing)$21.12M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Aug 12, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding57,911,892
10 Day Avg. Volume1,088,407
30 Day Avg. Volume1,090,294
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-29.14
Enterprise Value/Ebitda-10.54
Forecast
1Y Price Target
$54.50Price Target Upside57.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$127.58M
Bulls Say, Bears Say
Bulls Say
Manufacturing ReadinessManufacturing facility passed FDA inspection, resolved inspection findings, and is operational to support an initial commercial launch, addressing a key commercialization bottleneck.
Pivotal Clinical DataPivotal HOPE-3 trial met prespecified primary and cardiac secondary endpoints, showing reduced heart scarring, preserved cardiac function, and improved muscle performance versus placebo, strengthening the case for clinical benefit and approval.
Regulatory ProgressFDA resumed review of the biologics application, has not identified outstanding review issues since resumption, and offered an informal meeting, which reduces regulatory uncertainty and supports the path toward approval.
Bears Say
Financial And Funding RiskReported earnings per share missed analyst expectations and limited funding capacity could force dilution or slow development if additional capital is not secured.
Prior Regulatory SetbackA prior complete response letter and an original filing based on small open-label data created regulatory precedent for additional data requests, increasing the risk of further review setbacks.
Priority Review Voucher UncertaintyEligibility for a rare pediatric disease priority review voucher is uncertain because the governing legislation may not be renewed, which could remove a projected source of meaningful cash even if approval occurs.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics, Inc.’s price range in the past 12 months?
Capricor Therapeutics, Inc. lowest stock price was $4.30 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics, Inc.’s market cap?
Capricor Therapeutics, Inc.’s market cap is $1.67B.
When is Capricor Therapeutics, Inc.’s upcoming earnings report date?
Capricor Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 78 days.
How were Capricor Therapeutics, Inc.’s earnings last quarter?
Capricor Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.083.
Is Capricor Therapeutics, Inc. overvalued?
According to Wall Street analysts Capricor Therapeutics, Inc.’s price is currently Undervalued.
Does Capricor Therapeutics, Inc. pay dividends?
Capricor Therapeutics, Inc. does not currently pay dividends.
What is Capricor Therapeutics, Inc.’s EPS estimate?
Capricor Therapeutics, Inc.’s EPS estimate is -0.59.
How many shares outstanding does Capricor Therapeutics, Inc. have?
Capricor Therapeutics, Inc. has 57,911,892 shares outstanding.
What happened to Capricor Therapeutics, Inc.’s price movement after its last earnings report?
Capricor Therapeutics, Inc. reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went down -3.775%.
Which hedge fund is a major shareholder of Capricor Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.50 (57.06% Upside)
$54.50 (57.06% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 149.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.83%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
112.19%
Trailing 12-Months
Company Description
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
CAPR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory progress for deramiocel — statistically significant phase 3 efficacy (primary and cardiac secondary endpoints), robust long-term safety exposure, active BLA review with a clear PDUFA date, in-house manufacturing capabilities and a solid cash runway. Management also articulated a concrete commercialization plan and eligibility for a monetizable Priority Review Voucher. Offsetting these positives are notable near-term risks: an active lawsuit with NS Pharma that creates distribution uncertainty (and potential need to repay $50M), rising operating expenses and no current product revenue, manufacturing labeling constraints for an ultra-cold-chain therapy, and unresolved ASP/AMP payer complexities that could affect access. On balance, the material clinical/regulatory achievements and internal control of manufacturing and cash resources outweigh the legal and commercial execution risks, but the litigation and payer/pricing issues remain important near-term uncertainties.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$54.50
▲(57.06% Upside)
Technical Analysis
Ownership Overview
0.93% Insiders
7.71% Mutual Funds
27.28% Other Institutional Investors
54.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---